Brain Cancer | Specialty

Durvalumab Shows Durable Activity in Recurrent GBM

November 20th 2016

The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.

AG-120 Shows Early Efficacy in IDH1-Mutant Glioma

November 20th 2016

Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.

Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer

November 19th 2016

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

Optune Survival Benefit in GBM Sustained With Long-Term Data

November 19th 2016

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM

November 19th 2016

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Krista Qualmann on the Effect of Genetic Testing on Treatment in Brain Cancer

November 19th 2016

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

November 19th 2016

Checkpoint Inhibitors Show Promise in Glioblastoma

November 19th 2016

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM Study

November 18th 2016

Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.

Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM

November 18th 2016

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.

Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer

November 18th 2016

Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer

November 18th 2016

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

November 10th 2016

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.

Dr. Lukas on Immunotherapy in Glioblastoma

October 26th 2016

Rimas V. Lukas, MD, associate professor of Neurology, director, Medical Neuro-Oncology, University of Chicago Medicine, discusses some of the exciting advances recently seen with immunotherapy in the treatment of patients with glioblastoma

Computer Simulation Helps Plan Transducer Placement in Glioblastoma

October 13th 2016

For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.

NYU Scientist Sees Hope Peeking Through Gloom of Glioblastoma

October 4th 2016

Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.

Wearable Therapy Making Inroads in Oncology

September 30th 2016

Two headgear items, a system of applying electromagnetic currents to patients with glioblastoma and a cooling cap for individuals undergoing chemotherapy for breast cancer, are early entries in the field.

Early Potential Seen With Immunotherapy in Glioblastoma, But Questions Remain

August 26th 2016

David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

August 19th 2016

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Models Pave the Way for Improved Outcomes in Medulloblastoma

August 16th 2016

To discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.